Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Subklewe

Showing results (11-20 of 244) with videos related to

Pageof 25
Sort By:
Blood|December 4, 2024
Honing CAR T cells to tackle acute myeloid leukemiaSascha Haubner, Marion Subklewe, Michel Sadelain
Deutsche Medizinische Wochenschrift (1946)|May 15, 2024
[T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?]Veit Bücklein, Bastian von Tresckow, Marion Subklewe
Hematology. American Society of Hematology. Education Program|December 9, 2023
Recognizing, defining, and managing CAR-T hematologic toxicitiesKai Rejeski, Marion Subklewe, Frederick L Locke
Hematology. American Society of Hematology. Education Program|December 9, 2023
Novel immunotherapies in the treatment of AML: is there hope?Marion Subklewe, Veit Bücklein, David Sallman, et al.
Intensive Care Medicine|April 2, 2020
Ten things the hematologist wants you to know about CAR-T cellsBoris Böll, Marion Subklewe, Michael von Bergwelt-Baildon
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|June 28, 2019
Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer TherapyMarion Subklewe, Michael von Bergwelt-Baildon, Andreas Humpe
Molecular Immunology|April 18, 2015
Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignanciesGerhard Zugmaier, Matthias Klinger, Margit Schmidt, et al.
Current Opinion in Pharmacology|May 1, 2025
Novel approaches to CAR T cell target identification in acute myeloid leukemiaGordon Victor Hoffmann, Adrian Gottschlich, Marion Subklewe, et al.
Neurology|April 3, 2023
Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell TherapyPhilipp Karschnia, Kaj Rejeski, Marion Subklewe, et al.
Seminars in Hematology|June 27, 2015
Immunotherapy for Acute Myeloid LeukemiaFelix S Lichtenegger, Christina Krupka, Thomas Köhnke, et al.
Pageof 25

Showing results (11-20 of 244) with videos related to

Sort By:
Pageof 25
Blood|December 4, 2024
Honing CAR T cells to tackle acute myeloid leukemiaSascha Haubner, Marion Subklewe, Michel Sadelain
Deutsche Medizinische Wochenschrift (1946)|May 15, 2024
[T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?]Veit Bücklein, Bastian von Tresckow, Marion Subklewe
Hematology. American Society of Hematology. Education Program|December 9, 2023
Recognizing, defining, and managing CAR-T hematologic toxicitiesKai Rejeski, Marion Subklewe, Frederick L Locke
Hematology. American Society of Hematology. Education Program|December 9, 2023
Novel immunotherapies in the treatment of AML: is there hope?Marion Subklewe, Veit Bücklein, David Sallman, et al.
Intensive Care Medicine|April 2, 2020
Ten things the hematologist wants you to know about CAR-T cellsBoris Böll, Marion Subklewe, Michael von Bergwelt-Baildon
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|June 28, 2019
Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer TherapyMarion Subklewe, Michael von Bergwelt-Baildon, Andreas Humpe
Molecular Immunology|April 18, 2015
Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignanciesGerhard Zugmaier, Matthias Klinger, Margit Schmidt, et al.
Current Opinion in Pharmacology|May 1, 2025
Novel approaches to CAR T cell target identification in acute myeloid leukemiaGordon Victor Hoffmann, Adrian Gottschlich, Marion Subklewe, et al.
Neurology|April 3, 2023
Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell TherapyPhilipp Karschnia, Kaj Rejeski, Marion Subklewe, et al.
Seminars in Hematology|June 27, 2015
Immunotherapy for Acute Myeloid LeukemiaFelix S Lichtenegger, Christina Krupka, Thomas Köhnke, et al.
Pageof 25